<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="epm1" content-type="chapter" from-where="body" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">gene</book-id>
    <book-title-group>
      <book-title>GeneReviews<sup>&#x000ae;</sup></book-title>
    </book-title-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Adam</surname>
          <given-names>Margaret P</given-names>
        </name>
        <role>Editor-in-Chief</role>
      </contrib>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Ardinger</surname>
          <given-names>Holly H</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Pagon</surname>
          <given-names>Roberta A</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Wallace</surname>
          <given-names>Stephanie E</given-names>
        </name>
      </contrib>
      <role>Senior Editors</role>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Bean</surname>
          <given-names>Lora JH</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Mefford</surname>
          <given-names>Heather C</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Stephens</surname>
          <given-names>Karen</given-names>
        </name>
      </contrib>
      <role>Molecular Genetics</role>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Amemiya</surname>
          <given-names>Anne</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Ledbetter</surname>
          <given-names>Nikki</given-names>
        </name>
      </contrib>
      <role>Genetic Counseling</role>
    </contrib-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <year>1993</year>
    </pub-date>
    <pub-date publication-format="electronic" date-type="pubr">
      <year>2017</year>
    </pub-date>
    <issn>2372-0697</issn>
    <publisher>
      <publisher-name>University of Washington, Seattle</publisher-name>
      <publisher-loc>Seattle (WA)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 1993-2017, University of Washington, Seattle. GeneReviews is a registered trademark of the University of Washington, Seattle. All rights reserved.</copyright-statement>
      <copyright-year>2017</copyright-year>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://www.ncbi.nlm.nih.gov/books/NBK138602/">
        <license-p>GeneReviews&#x000ae; chapters are owned by the University of Washington. Permission is hereby granted to reproduce, distribute, and translate copies of content materials for noncommercial research purposes only, provided that (i) credit for source (<ext-link ext-link-type="uri" xlink:href="http://www.genereviews.org/">http://www.genereviews.org/</ext-link>) and copyright (&#x000a9; 1993-2017 University of Washington) are included with each copy; (ii) a link to the original material is provided whenever the material is published elsewhere on the Web; and (iii) reproducers, distributors, and/or translators comply with the <related-object source-id="gene" document-id="GRcopyright_permiss">GeneReviews&#x000ae; Copyright Notice and Usage Disclaimer</related-object>. No further modifications are allowed. For clarity, excerpts of GeneReviews chapters for use in lab reports and clinic notes are a permitted use.</license-p>
        <license-p>For more information, see the <related-object source-id="gene" document-id="GRcopyright_permiss">GeneReviews&#x000ae; Copyright Notice and Usage Disclaimer</related-object>.</license-p>
        <license-p>For questions regarding permissions or whether a specified use is allowed, contact: <email>admasst@uw.edu</email>.</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Genetics</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Medicine</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Diseases</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="ednotes">
      <p content-type="genetic_counseling">
<italic toggle="yes">Genetic counseling is the process of
providing individuals and families with information on the nature, inheritance,
and implications of genetic disorders to help them make informed medical and
personal decisions. The following section deals with genetic risk assessment and
the use of family history and genetic testing to clarify genetic status for
family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with
a genetics professional</italic>. &#x02014;ED.</p>
      <p content-type="resources">
<italic toggle="yes">GeneReviews staff has selected the following disease-specific and/or
umbrella support organizations and/or registries for the benefit of individuals
with this disorder and their families. GeneReviews is not responsible for the
information provided by other organizations. For information on selection
criteria, click <related-object source-id="gene" document-id="app4">here</related-object>.</italic></p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <book-part-id book-part-id-type="pmcid">epm1</book-part-id>
      <title-group>
        <title>Unverricht-Lundborg Disease</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Lehesjoki</surname>
            <given-names>Anna-Elina</given-names>
          </name>
          <degrees>MD, PhD</degrees>
          <aff>Folkhalsan Institute of Genetics and Neuroscience Center <break/>University of Helsinki <break/>Helsinki, Finland</aff>
          <email>anna-elina.lehesjoki@helsinki.fi</email>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>K&#x000e4;lvi&#x000e4;inen</surname>
            <given-names>Reetta</given-names>
          </name>
          <degrees>MD, PhD</degrees>
          <aff>Kuopio Epilepsy Center<break/>Kuopio University Hospital<break/>Kuopio, Finland</aff>
          <email>reetta.kalviainen@kuh.fi</email>
        </contrib>
      </contrib-group>
      <pub-history>
        <date date-type="created">
          <day>24</day>
          <month>6</month>
          <year>2004</year>
        </date>
        <date date-type="updated">
          <day>26</day>
          <month>11</month>
          <year>2014</year>
        </date>
        <date date-type="revised">
          <day>18</day>
          <month>9</month>
          <year>2007</year>
        </date>
      </pub-history>
      <related-object link-type="parent-book-link" source-id="gene">GeneReviews<sup>&#x000ae;</sup></related-object>
      <related-object link-type="previous-part-link" source-id="gene" document-id="udd" document-type="chapter">Udd Distal Myopathy</related-object>
      <related-object link-type="next-part-link" source-id="gene" document-id="ucd-overview" document-type="chapter">Urea Cycle Disorders Overview</related-object>
      <abstract id="epm1.Summary">
        <title>Summary</title>
        <sec>
          <title>Clinical characteristics</title>
          <p>Unverricht-Lundborg disease (EPM1) is a neurodegenerative disorder characterized by onset from age six to 15 years, stimulus-sensitive myoclonus, and tonic-clonic epileptic seizures. Some years after the onset, ataxia, incoordination, intentional tremor, and dysarthria develop. Individuals with EPM1 are mentally alert but show emotional lability, depression, and mild decline in intellectual performance over time.</p>
        </sec>
        <sec>
          <title>Diagnosis/testing</title>
          <p>EPM1 results from defective function of cystatin B, a cysteine protease inhibitor, as a consequence of mutation of <italic toggle="yes">CSTB</italic>. The diagnosis can be confirmed by identifying the common dodecamer repeat expansion or other pathogenic variants in <italic toggle="yes">CSTB</italic>.</p>
        </sec>
        <sec>
          <title>Management</title>
          <p><italic toggle="yes">Treatment of manifestations:</italic> Symptomatic pharmacologic and rehabilitative management, including psychosocial support, are the mainstay of care; valproic acid, the first drug of choice, diminishes myoclonus and the frequency of generalized seizures; clonazepam, approved by FDA for the treatment of myoclonic seizures, is an add-on therapy; high-dose piracetam is used to treat myoclonus; levetiracetam appears to be effective for both myoclonus and generalized seizures. Topiramate and zonisamide may also be used as add-on therapy.</p>
          <p><italic toggle="yes">Surveillance:</italic> Lifelong clinical follow up, including evaluation of drug treatment and rehabilitation.</p>
          <p><italic toggle="yes">Agents/circumstances to avoid:</italic> Phenytoin aggravates neurologic symptoms or even accelerates cerebellar degeneration; sodium channel blockers (carbamazepine, oxcarbazepine), GABAergic drugs (tiagabine, vigabatrin) and gabapentin and pregabalin may aggravate myoclonus and myoclonic seizures.</p>
        </sec>
        <sec>
          <title>Genetic counseling</title>
          <p>EPM1 is inherited in an autosomal recessive manner. At conception, each sib of an affected individual has a 25% chance of being affected, a 50% chance of being an asymptomatic carrier, and a 25% chance of being unaffected and not a carrier. Carrier testing for at-risk relatives and prenatal testing for pregnancies at increased risk are possible if both <italic toggle="yes">CSTB</italic> pathogenic variants in a family are known.</p>
        </sec>
      </abstract>
    </book-part-meta>
    <body>
      <sec id="epm1.Diagnosis">
        <title>Diagnosis</title>
        <p>The diagnosis of Unverricht-Lundborg disease (EPM1) is suspected in a previously healthy child age six to 15 years who manifests the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>Involuntary, action-activated myoclonic jerks</p>
            <p>AND/OR</p>
          </list-item>
          <list-item>
            <p>Generalized tonic-clonic seizures</p>
          </list-item>
          <list-item>
            <p>Photosensitive, generalized spike-and-wave and polyspike-and-wave paroxysms on EEG. The EEG is always abnormal, even before the onset of symptoms. The background activity is labile and may be slower than normal. Photosensitivity is marked.</p>
          </list-item>
          <list-item>
            <p>A gradual worsening of the neurologic symptoms (myoclonus and ataxia)</p>
          </list-item>
          <list-item>
            <p>Normal brain MRI</p>
          </list-item>
        </list>
        <p><bold>Gene.</bold>
<italic toggle="yes">CSTB</italic> is the only gene in which pathogenic variants are known to cause Unverricht-Lundborg disease [<xref ref-type="bibr" rid="epm1.REF.pennacchio.1998.251">Pennacchio et al 1998</xref>]. Virtually all affected individuals have an unstable expansion of a 12-nucleotide (dodecamer) repeat 5'-CCC-CGC-CCC-GCG-3' (<xref ref-type="table" rid="epm1.T.selected_cstb_pathogenic_variants">g.513685_513696</xref>) in the promoter region in at least one of the two altered <italic toggle="yes">CSTB</italic> alleles; the majority of individuals have two expanded repeats in the abnormal allele range.</p>
        <p>
          <bold>Allele sizes</bold>
        </p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Normal alleles.</bold> 2-3 dodecamer repeats</p>
          </list-item>
          <list-item>
            <p><bold>Full-penetrance alleles.</bold> &#x02265;30 dodecamer repeats. The largest allele observed to date using Southern blotting is approximately 125 dodecamer repeats (see <xref ref-type="table" rid="epm1.T.selected_cstb_pathogenic_variants">Table 2</xref>).</p>
          </list-item>
          <list-item>
            <p>
              <bold>Alleles of questionable significance</bold>
            </p>
            <list list-type="bullet">
              <list-item>
                <p>Alleles of 12-17 dodecamer repeats <xref ref-type="table" rid="epm1.T.selected_cstb_pathogenic_variants">g.513685_513696(12_17)</xref> have been observed, but individuals with alleles in this range have not undergone thorough clinical evaluation for signs and symptoms of EPM1.</p>
              </list-item>
              <list-item>
                <p>Alleles of 4-11 dodecamer repeats and 18-29 dodecamer repeats <xref ref-type="table" rid="epm1.T.selected_cstb_pathogenic_variants">g.513685_513696(18_29)</xref> have not been reported.</p>
              </list-item>
            </list>
          </list-item>
        </list>
        <p>
          <bold>Clinical testing</bold>
        </p>
        <table-wrap id="epm1.T.summary_of_molecular_genetic_test" orientation="portrait" position="anchor">
          <label>Table 1. </label>
          <caption>
            <p>Summary of Molecular Genetic Testing Used in Unverricht-Lundborg Disease</p>
          </caption>
          <table frame="hsides" rules="groups">
            <thead>
              <tr>
                <th id="hd_h_epm1.T.summary_of_molecular_genetic_test_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Gene&#x000a0;<sup>1</sup></th>
                <th id="hd_h_epm1.T.summary_of_molecular_genetic_test_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Test Method</th>
                <th id="hd_h_epm1.T.summary_of_molecular_genetic_test_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Proportion of Probands with a Pathogenic Variant Detectable by This Method</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td headers="hd_h_epm1.T.summary_of_molecular_genetic_test_1_1_1_1" rowspan="3" valign="middle" align="left" scope="row" colspan="1">
                  <italic toggle="yes">CSTB</italic>
                </td>
                <td headers="hd_h_epm1.T.summary_of_molecular_genetic_test_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Targeted analysis for <xref ref-type="table" rid="epm1.T.selected_cstb_pathogenic_variants">g.513685_513696(30_125)</xref>&#x000a0;<sup>2</sup></td>
                <td headers="hd_h_epm1.T.summary_of_molecular_genetic_test_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">99%&#x000a0;<sup>3</sup><break/>~90%&#x000a0;<sup>4</sup></td>
              </tr>
              <tr>
                <td headers="hd_h_epm1.T.summary_of_molecular_genetic_test_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Targeted analysis for pathogenic variants&#x000a0;<sup>5,&#x000a0;6</sup></td>
                <td headers="hd_h_epm1.T.summary_of_molecular_genetic_test_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Unknown</td>
              </tr>
              <tr>
                <td headers="hd_h_epm1.T.summary_of_molecular_genetic_test_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Sequence analysis&#x000a0;<sup>7,&#x000a0;8</sup></td>
                <td headers="hd_h_epm1.T.summary_of_molecular_genetic_test_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Unknown</td>
              </tr>
            </tbody>
          </table>
          <table-wrap-foot>
            <fn id="epm1.TF.1.1">
              <label>1. </label>
              <p>See <related-object source-id="gene" document-id="epm1" object-id="epm1.molgen.TA">Table A. Genes and Databases</related-object> for chromosome locus and protein. See <xref ref-type="sec" rid="epm1.Molecular_Genetics">Molecular Genetics</xref> for information on allelic variants.</p>
            </fn>
            <fn id="epm1.TF.1.2">
              <label>2. </label>
              <p>Alleles with dodecamer repeat expansion 30 to ~125</p>
            </fn>
            <fn id="epm1.TF.1.3">
              <label>3. </label>
              <p>99% of disease alleles in Finnish individuals</p>
            </fn>
            <fn id="epm1.TF.1.4">
              <label>4. </label>
              <p>90% of disease alleles worldwide</p>
            </fn>
            <fn id="epm1.TF.1.5">
              <label>5. </label>
              <p>c.10G&#x0003e;C, c.67-1G&#x0003e;C, c.169-2A&#x0003e;G, c.202C&#x0003e;T, c.218_219delTC</p>
            </fn>
            <fn id="epm1.TF.1.6">
              <label>6. </label>
              <p>Pathogenic variants included in a panel may vary by laboratory.</p>
            </fn>
            <fn id="epm1.TF.1.7">
              <label>7. </label>
              <p>Sequence analysis detects variants that are benign, likely benign, of uncertain significance, likely pathogenic, or pathogenic. Pathogenic variants may include small intragenic deletions/insertions and missense, nonsense, and splice site variants; typically, exon or whole-gene deletions/duplications are not detected. For issues to consider in interpretation of sequence analysis results, click <related-object link-type="booklink" source-id="gene" document-id="app2" document-type="appendix">here</related-object>.</p>
            </fn>
            <fn id="epm1.TF.1.8">
              <label>8. </label>
              <p>Detects the five <italic toggle="yes">CSTB</italic> pathogenic variants noted in footnote 5 as well as novel variants.</p>
            </fn>
          </table-wrap-foot>
        </table-wrap>
        <sec id="epm1.Testing_Strategy">
          <title>Testing Strategy</title>
          <p>
            <bold>Confirming the diagnosis in a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>Targeted molecular genetic testing for the dodecamer expansion of <italic toggle="yes">CSTB</italic> should be pursued first.</p>
            </list-item>
            <list-item>
              <p>When heterozygosity for the dodecamer expansion is found in an affected individual, it is appropriate to pursue molecular genetic testing for other <italic toggle="yes">CSTB</italic> pathogenic variants in the second allele either by targeted analysis for a broader panel of pathogenic variants or by sequence analysis.</p>
            </list-item>
          </list>
        </sec>
      </sec>
      <sec id="epm1.Clinical_Characteristics">
        <title>Clinical Characteristics</title>
        <sec id="epm1.Clinical_Description">
          <title>Clinical Description</title>
          <p>In more than half of individuals with Unverricht-Lundborg disease (EPM1), the first symptom is involuntary myoclonic jerks [<xref ref-type="bibr" rid="epm1.REF.k_lvi_inen.2008.549">K&#x000e4;lvi&#x000e4;inen et al 2008</xref>]. The myoclonic jerks are action activated and stimulus sensitive, and may be provoked by light, physical exertion, and stress. They occur predominantly in the proximal muscles of the extremities and are asynchronous; they may be focal or multifocal and may generalize to a series of myoclonic seizures or even status myoclonicus (continuous myoclonic jerks involving a semi-loss of consciousness).</p>
          <p>During the first five to ten years, the symptoms/myoclonic jerks characteristically progress and about one third of affected individuals become severely incapacitated (wheelchair bound). Although the myoclonic jerks are disabling and resistant to therapy, the individual usually learns to tolerate them over time, provided that the psychosocial support is good and depression not too severe.</p>
          <p>In almost half of individuals, the presenting symptom is tonic-clonic seizures. There may also be absence, psychomotor, and/or focal motor seizures. Epileptic seizures, infrequent in the early stages of the disease, often increase in frequency during the ensuing three to seven years. Later they may cease entirely with appropriate antiepileptic drug treatment. In rare cases, tonic-clonic seizures do not occur.</p>
          <p>Neurologic findings initially seem normal; however, experienced observers usually note recurrent, almost imperceptible myoclonus, especially in response to photic stimuli or other stimuli (threat, clapping of hands, nose tapping, reflexes) or to action (movements made during neurologic examination) or to cognitive stimuli (task demanding cognitive and psychomotor processing). Some years after the onset, ataxia, incoordination, intentional tremor, and dysarthria develop.</p>
          <p>Individuals with EPM1 have normal cognition but show emotional lability, depression, and mild decline in intellectual performance over time.</p>
          <p>The disease course is inevitably progressive; however, the rate of deterioration especially in terms of walking capacity appears to vary even within the same family. Generalized tonic-clonic seizures are usually controlled with treatment, but myoclonic jerks may become severe, appear in series, and inhibit normal activities [<xref ref-type="bibr" rid="epm1.REF.magaudda.2006.860">Magaudda et al 2006</xref>]. Myoclonic jerks may also be subcortical in origin and therefore difficult to control [<xref ref-type="bibr" rid="epm1.REF.danner.2009.81">Danner et al 2009</xref>]. The individual becomes depressed and progression ensues. Education is often interrupted because of emotional, social, and intellectual problems.</p>
          <p>In the past, life span was shortened; many individuals died eight to 15 years after the onset of disease, usually before age 30 years. With better pharmacologic, physiotherapeutic, and psychosocial supportive treatment, life expectancy appears to be near normal [<xref ref-type="bibr" rid="epm1.REF.k_lvi_inen.2008.549">K&#x000e4;lvi&#x000e4;inen et al 2008</xref>].</p>
        </sec>
        <sec id="epm1.GenotypePhenotype_Correlations">
          <title>Genotype-Phenotype Correlations</title>
          <p>Individuals with pathogenic variants in <italic toggle="yes">CSTB</italic> develop similar disease manifestations. There is preliminary evidence that correlation exists between the length of the expanded dodecamer repeat and the age of onset or disease severity [Author, personal communication]. However, disease severity also varies among affected individuals within a family with apparently similar repeat-size expansions. Moreover EPM1 resulting from compound heterozygous <italic toggle="yes">CSTB</italic> pathogenic variants (a dodecamer repeat expansion on one allele and a single nucleotide variant or indel variant on the other allele) presents with earlier age of onset, more severe myoclonus, and seizures that may be drug-resistant [<xref ref-type="bibr" rid="epm1.REF.koskenkorva.2011.515">Koskenkorva et al 2011</xref>, <xref ref-type="bibr" rid="epm1.REF.canafoglia.2012.2120">Canafoglia et al 2012</xref>]. The presence of variable phenotypes (even in siblings) suggests that interactions with other genetic factors influence the final disease presentation.</p>
        </sec>
        <sec id="epm1.Nomenclature">
          <title>Nomenclature</title>
          <p>Unverricht-Lundborg disease was previously called Baltic myoclonus or Baltic myoclonic epilepsy. These names should no longer be used because the condition occurs worldwide.</p>
          <p>An identical disorder, found in individuals from the Mediterranean countries and called Mediterranean myoclonus, is now known to be EPM1. The term progressive myoclonus epilepsy (PME) covers a large and varied group of diseases characterized by myoclonus, epilepsy, and progressive neurologic deterioration.</p>
        </sec>
        <sec id="epm1.Prevalence">
          <title>Prevalence</title>
          <p>EPM1 is the major cause of progressive myoclonus epilepsy in North America; exact prevalence figures are not available.</p>
          <p>EPM1 occurs worldwide, but its prevalence is increased in certain populations: in the North African countries of Tunisia, Algeria, and Morocco, where exact prevalence figures are not available; and in Finland, where its prevalence (1:25,000) is higher than anywhere else in the world. The incidence in Finland is estimated at 1:20,000 births.</p>
        </sec>
      </sec>
      <sec id="epm1.Genetically_Related_Allelic_Disorde">
        <title>Genetically Related (Allelic) Disorders</title>
        <p>No phenotypes other than those discussed in this <italic toggle="yes">GeneReview</italic> are known to be associated with mutation of <italic toggle="yes">CSTB</italic>.</p>
      </sec>
      <sec id="epm1.Differential_Diagnosis">
        <title>Differential Diagnosis</title>
        <p>At the onset of Unverricht-Lundborg disease (EPM1), juvenile myoclonic epilepsy (JME) &#x02013; which has a favorable outcome &#x02013;should be considered as a diagnostic alternative. Individuals with JME have a normal neurologic examination and the background of the EEG is undisturbed.</p>
        <p>In case of progression, other forms of progressive myoclonus epilepsy, notably <related-object link-type="booklink" source-id="gene" document-id="merrf" document-type="chapter">myoclonic epilepsy with ragged red fibers</related-object> (MERRF), <related-object link-type="booklink" source-id="gene" document-id="ncl" document-type="chapter">neuronal ceroid-lipofuscinoses</related-object>, and <related-object link-type="booklink" source-id="gene" document-id="lafora" document-type="chapter">Lafora disease</related-object>, should be considered:</p>
        <p>In individuals with an EPM1-like phenotype in whom a <italic toggle="yes">CSTB</italic> pathogenic variant is not identified, the following four disorders should be considered.</p>
        <list list-type="bullet">
          <list-item>
            <p>An EPM1-like <related-object link-type="booklink" source-id="gene" document-id="me-ataxia" document-type="chapter">progressive myoclonus epilepsy-ataxia syndrome</related-object> has been shown to result from a missense pathogenic variant in <italic toggle="yes">PRICKLE1</italic> [<xref ref-type="bibr" rid="epm1.REF.bassuk.2008.572">Bassuk et al 2008</xref>]. Children present with ataxia at age four to five years and later develop a progressive myoclonus epilepsy phenotype with mild or absent cognitive decline.</p>
          </list-item>
          <list-item>
            <p><related-object link-type="booklink" source-id="gene" document-id="amrf" document-type="chapter">Action myoclonus &#x02013; renal failure syndrome</related-object> (myoclonus-renal failure, AMRF) is caused by pathogenic variants in <italic toggle="yes">SCARB2</italic> [<xref ref-type="bibr" rid="epm1.REF.berkovic.2008.673">Berkovic et al 2008</xref>]. AMRF typically presents at ages 15 to 25 years either with neurologic symptoms (including tremor, action myoclonus, seizures, and ataxia) or with proteinuria that progresses to renal failure.</p>
          </list-item>
          <list-item>
            <p>Progressive myoclonus epilepsy-6 (EPM6) is caused by homozygous pathogenic variants in <italic toggle="yes">GOSR2</italic> [<xref ref-type="bibr" rid="epm1.REF.corbett.2011.657">Corbett et al 2011</xref>, <xref ref-type="bibr" rid="epm1.REF.boiss_lomax.2013.1146">Boiss&#x000e9; Lomax et al 2013</xref>]. EPM6 presents with early-onset ataxia (average age 2 years), followed by action myoclonus and seizures later in childhood. Independent ambulation is lost in the second decade and affected individuals develop scoliosis by adolescence. Cognition is not usually affected.</p>
          </list-item>
          <list-item>
            <p>The disorder myoclonus epilepsy and ataxia due to pathogenic variants in the potassium channel (MEAK), caused by a recurrent <italic toggle="yes">de novo</italic> missense variant in <italic toggle="yes">KCNC1</italic>, resembles EPM1 at disease onset [<xref ref-type="bibr" rid="epm1.REF.muona.2015.39">Muona et al 2015</xref>]. MEAK presents between ages six and 15 years with myoclonus (sometimes reported as tremor). The later disease course is characterized by moderate to severe incapacitating myoclonus, infrequent tonic-clonic seizures, ataxia, and mild (if any) cognitive decline. The clinical course for MEAK is generally more severe than for EPM1.</p>
          </list-item>
        </list>
        <p>See <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://omim.org/phenotypicSeries/PS254800">Epilepsy, progressive myoclonic: OMIM Phenotypic Series</ext-link> to view genes associated with this phenotype in OMIM.</p>
      </sec>
      <sec id="epm1.Management">
        <title>Management</title>
        <sec id="epm1.Evaluations_Following_Initial_Diagn">
          <title>Evaluations Following Initial Diagnosis</title>
          <p>To establish the extent of disease and needs in an individual diagnosed with Unverricht-Lundborg disease (EPM1), the following evaluations are recommended:</p>
          <list list-type="bullet">
            <list-item>
              <p>Clinical evaluation including walking, coordination, handwriting, school performance, and emotional features</p>
            </list-item>
            <list-item>
              <p>Examination of myoclonus including evaluation of myoclonus at rest, with action, and in response to stimuli</p>
            </list-item>
            <list-item>
              <p>EEG evaluation before initiation of therapy, as it is most characteristic before use of anticonvulsive medication</p>
            </list-item>
            <list-item>
              <p>Clinical genetics consultation</p>
            </list-item>
          </list>
        </sec>
        <sec id="epm1.Treatment_of_Manifestations">
          <title>Treatment of Manifestations</title>
          <p>Symptomatic pharmacologic and rehabilitative management are the mainstay of patient care [<xref ref-type="bibr" rid="epm1.REF.k_lvi_inen.2008.549">K&#x000e4;lvi&#x000e4;inen et al 2008</xref>]:</p>
          <list list-type="bullet">
            <list-item>
              <p><bold>Valproic acid</bold> is the first drug of choice. It diminishes myoclonus and the frequency of generalized seizures.</p>
            </list-item>
            <list-item>
              <p><bold>Clonazepam,</bold> the only drug approved by the Food and Drug Administration (FDA) for the treatment of myoclonic seizures, is used as add-on therapy [<xref ref-type="bibr" rid="epm1.REF.shahwan.2005.239">Shahwan et al 2005</xref>].</p>
            </list-item>
            <list-item>
              <p><bold>High-dose piracetam</bold> has been formally studied and has been found useful in the treatment of myoclonus [<xref ref-type="bibr" rid="epm1.REF.koskiniemi.1998.344">Koskiniemi et al 1998</xref>].</p>
            </list-item>
            <list-item>
              <p><bold>Levetiracetam</bold> has been evaluated in several series and seems to be effective for both myoclonus and generalized seizures.</p>
            </list-item>
            <list-item>
              <p><bold>Topiramate</bold> and <bold>zonisamide</bold> may also be used as add-on therapies<bold>.</bold></p>
            </list-item>
          </list>
        </sec>
        <sec id="epm1.Surveillance">
          <title>Surveillance</title>
          <p>Patients need lifelong clinical follow up and psychosocial support including evaluation of the drug treatment and comprehensive rehabilitation.</p>
        </sec>
        <sec id="epm1.AgentsCircumstances_to_Avoid">
          <title>Agents/Circumstances to Avoid</title>
          <p><bold>Phenytoin</bold> should be avoided, as it has been found to have aggravating side effects on the associated neurologic symptoms, and may even accelerate cerebellar degeneration [<xref ref-type="bibr" rid="epm1.REF.eldridge.1983.838">Eldridge et al 1983</xref>].</p>
          <p><bold>Sodium channel blockers</bold> (carbamazepine, oxcarbazepine, phenytoin) and <bold>GABAergic drugs</bold> (tiagabine, vigabatrin) as well as <bold>gabapentin</bold> and <bold>pregabalin</bold> should in general be avoided as they may aggravate myoclonus and myoclonic seizures [<xref ref-type="bibr" rid="epm1.REF.medina.2005.307">Medina et al 2005</xref>].</p>
        </sec>
        <sec id="epm1.Evaluation_of_Relatives_at_Risk">
          <title>Evaluation of Relatives at Risk</title>
          <p>It is appropriate to evaluate the older and younger sibs of a proband in order to identify as early as possible those who would benefit from institution of treatment and preventive measures. If the pathogenic variants in the family are known, molecular genetic testing can be used to clarify the genetic status of at-risk sibs.</p>
          <p>See <xref ref-type="sec" rid="epm1.Related_Genetic_Counseling_Issues">Genetic Counseling</xref> for issues related to testing of at-risk relatives for genetic counseling purposes.</p>
        </sec>
        <sec id="epm1.Therapies_Under_Investigation">
          <title>Therapies Under Investigation</title>
          <p>Brivaracetam, a SV2A ligand that differs from levetiracetam by its mechanism of action profile, has demonstrated significant antiepileptic activity in experimental models of epilepsy and myoclonus. Brivaracetam has been granted orphan drug designation by the FDA (United States) for the treatment of symptomatic myoclonus, and by the EMEA (European Agency for the Evaluation of Medicinal Products; European Union) for the treatment of progressive myoclonic epilepsies.</p>
          <p>Brivaracetam is currently being investigated as an add-on treatment for Unverricht-Lundborg disease in adolescents and adults.</p>
          <p>Search <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://clinicaltrials.gov/">ClinicalTrials.gov</ext-link> for access to information on clinical studies for a wide range of diseases and conditions.</p>
        </sec>
        <sec id="epm1.Other">
          <title>Other</title>
          <p>Vagus nerve stimulator therapy reduces seizures and significantly improves cerebellar function on neurologic examination [<xref ref-type="bibr" rid="epm1.REF.smith.2000.1046">Smith et al 2000</xref>].</p>
          <p>N-acetylcysteine has been tried with variable results [<xref ref-type="bibr" rid="epm1.REF.edwards.2002.1447">Edwards et al 2002</xref>].</p>
        </sec>
      </sec>
      <sec id="epm1.Genetic_Counseling">
        <title>Genetic Counseling</title>
        <sec id="epm1.Mode_of_Inheritance">
          <title>Mode of Inheritance</title>
          <p>Unverricht-Lundborg disease (EPM1) is inherited in an autosomal recessive manner.</p>
        </sec>
        <sec id="epm1.Risk_to_Family_Members">
          <title>Risk to Family Members</title>
          <p>
            <bold>Parents of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The parents of an affected child are obligate heterozygotes and therefore carry one <italic toggle="yes">CSTB</italic> pathogenic variant.</p>
            </list-item>
            <list-item>
              <p>Heterozygotes (carriers) are asymptomatic.</p>
            </list-item>
          </list>
          <p>
            <bold>Sibs of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>At conception, each sib of an affected individual has a 25% chance of being affected, a 50% chance of being an asymptomatic carrier, and a 25% chance of being unaffected and not a carrier.</p>
            </list-item>
            <list-item>
              <p>Once an at-risk sib is known to be unaffected, the risk of his/her being a carrier of a <italic toggle="yes">CSTB</italic> pathogenic variant is 2/3.</p>
            </list-item>
            <list-item>
              <p>Heterozygotes (carriers) are asymptomatic.</p>
            </list-item>
          </list>
          <p>
            <bold>Offspring of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>Several individuals with Unverricht-Lundborg disease, both males and females, have produced children.</p>
            </list-item>
            <list-item>
              <p>The offspring of an individual with Unverricht-Lundborg disease are obligate heterozygotes (carriers) for a pathogenic variant in <italic toggle="yes">CSTB</italic>.</p>
            </list-item>
            <list-item>
              <p>Because of the low carrier rate in the general population, the risk that an affected individual would have children with a carrier is extremely low except in genetic isolates.</p>
            </list-item>
          </list>
          <p><bold>Other family members of a proband.</bold> Each sib of the proband's parents is at a 50% risk of being a carrier.</p>
        </sec>
        <sec id="epm1.Carrier_Detection">
          <title>Carrier Detection</title>
          <p>Carrier testing is possible once the pathogenic variants have been identified in the family.</p>
          <p>Carrier testing for the reproductive partners of a known carrier is possible.</p>
        </sec>
        <sec id="epm1.Related_Genetic_Counseling_Issues">
          <title>Related Genetic Counseling Issues</title>
          <p>See Management, <xref ref-type="sec" rid="epm1.Evaluation_of_Relatives_at_Risk">Evaluation of Relatives at Risk</xref> for information on evaluating at-risk relatives for the purpose of early diagnosis and treatment.</p>
          <p>
            <bold>Family planning</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The optimal time for determination of genetic risk, clarification of carrier status, and discussion of the availability of prenatal testing is before pregnancy.</p>
            </list-item>
            <list-item>
              <p>It is appropriate to offer genetic counseling (including discussion of potential risks to offspring and reproductive options) to young adults who are affected, are carriers, or are at risk of being carriers.</p>
            </list-item>
          </list>
          <p><bold>Testing of asymptomatic individuals younger than age 18 years.</bold> Because practically all affected individuals have their first symptoms before age 18 years, requests from parents for testing of asymptomatic at-risk individuals younger than age 18 years may arise. Consensus holds that asymptomatic individuals younger than age 18 years who are at risk for adult-onset disorders for which no treatment exists is not considered appropriate, primarily because it negates the autonomy of the child with no compelling benefit. Further, concern exists regarding the potential unhealthy adverse effects that such information may have on family dynamics, the risk of discrimination and stigmatization in the future, and the anxiety that such information may cause.</p>
          <p>Testing is appropriate to consider in symptomatic individuals in a family with an established diagnosis of EPM1 regardless of age.</p>
          <p>For more information, see also the National Society of Genetic Counselors <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://nsgc.org/p/bl/et/blogid=47&#x00026;blogaid=28">position statement</ext-link> on genetic testing of minors for adult-onset conditions and the American Academy of Pediatrics and American College of Medical Genetics and Genomics <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://pediatrics.aappublications.org/content/131/3/620.full.pdf">policy statement</ext-link>: ethical and policy issues in genetic testing and screening of children.</p>
          <p><bold>Testing of at-risk asymptomatic adult relatives of individuals with EPM1</bold> is possible after molecular genetic testing has identified the specific pathogenic variants in the family. Such testing should be performed in the context of formal genetic counseling. This testing is not useful in predicting age of onset, severity, type of symptoms, or rate of progression in asymptomatic individuals. Testing of asymptomatic at-risk individuals with nonspecific or equivocal symptoms is predictive testing, not diagnostic testing.</p>
          <p><bold>DNA banking</bold> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of affected individuals.</p>
        </sec>
        <sec id="epm1.Prenatal_Testing_and_Preimplantatio">
          <title>Prenatal Testing and Preimplantation Genetic Diagnosis</title>
          <p>Once both <italic toggle="yes">CSTB</italic> pathogenic variants have been identified in an affected family member, prenatal testing for a pregnancy at increased risk and preimplantation genetic diagnosis for EPM1 are possible.</p>
          <p>Requests for prenatal testing for conditions such as Unverricht-Lundborg are not common. Differences in perspective may exist among medical professionals and within families regarding the use of prenatal testing, particularly if the testing is being considered for the purpose of pregnancy termination rather than early diagnosis. Although most centers would consider decisions about prenatal testing to be the choice of the parents, discussion of these issues is appropriate.</p>
        </sec>
      </sec>
      <sec id="epm1.Resources">
        <title>Resources</title>
      </sec>
      <sec id="epm1.Molecular_Genetics">
        <title>Molecular Genetics</title>
        <p><bold>Gene structure.</bold>
<italic toggle="yes">CSTB</italic> consists of three exons, all of them coding, which span roughly 2.5 kb of genomic DNA. Northern blot analysis shows a single transcript of approximately 0.8 kb. For a detailed summary of gene and protein information, see <related-object source-id="gene" document-id="epm1" object-id="epm1.molgen.TA">Table A</related-object>, <bold>Gene</bold>.</p>
        <p><bold>Pathogenic variants.</bold> Fourteen different pathogenic variants have been identified [<xref ref-type="bibr" rid="epm1.REF.kagitanishimono.2002.55">Kagitani-Shimono et al 2002</xref>, <xref ref-type="bibr" rid="epm1.REF.de_haan.2004.1061">de Haan et al 2004</xref>, <xref ref-type="bibr" rid="epm1.REF.joensuu.2007.185">Joensuu et al 2007</xref>, <xref ref-type="bibr" rid="epm1.REF.erdinc.2010.1">Erdinc et al 2010</xref>, <xref ref-type="bibr" rid="epm1.REF.canafoglia.2012.2120">Canafoglia et al 2012</xref>, <xref ref-type="bibr" rid="epm1.REF.pinto.2012.187">Pinto et al 2012</xref>].</p>
        <p>Among the more than 150 apparently unrelated families studied to date, all but one affected individual had at least one <italic toggle="yes">CSTB</italic> allele with an unstable expansion of a 12-nucleotide (dodecamer; 5'-CCC-CGC-CCC-GCG-3') repeat unit. The majority of affected individuals have this pathogenic variant on both alleles. The expanded repeat is located 175 bp upstream from the translation initiation codon in the promoter region of <italic toggle="yes">CSTB</italic>. This pathogenic variant accounts for approximately 90% of Unverricht-Lundborg disease alleles found throughout the world, and 99% of affected Finnish individuals have two disease-causing dodecamer expansions.</p>
        <p>Thirteen pathogenic variants occur in the transcription unit of <italic toggle="yes">CSTB</italic> (<xref ref-type="table" rid="epm1.T.selected_cstb_pathogenic_variants">Table 2</xref>). The c.67-1G&#x0003e;C, c.202C&#x0003e;T, c.168+2_168+21delinsAA, and c.218_219delTC pathogenic variants have been observed in more than one affected individual; the remaining nine have been identified in one individual each. The c.10G&#x0003e;C and c.66G&#x0003e;A pathogenic variants are the only two pathogenic variants reported in <italic toggle="yes">CSTB</italic> that do not occur in a compound heterozygous form with the dodecamer repeat expansion.</p>
        <table-wrap id="epm1.T.selected_cstb_pathogenic_variants" orientation="portrait" position="anchor">
          <label>Table 2. </label>
          <caption>
            <p>Selected <italic toggle="yes">CSTB</italic> Pathogenic Variants</p>
          </caption>
          <table frame="hsides" rules="groups">
            <thead>
              <tr>
                <th id="hd_h_epm1.T.selected_cstb_pathogenic_variants_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">DNA Nucleotide Change</th>
                <th id="hd_h_epm1.T.selected_cstb_pathogenic_variants_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Predicted Protein Change</th>
                <th id="hd_h_epm1.T.selected_cstb_pathogenic_variants_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Reference Sequences</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td headers="hd_h_epm1.T.selected_cstb_pathogenic_variants_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">g.513685_513696(30_125) (dodecamer repeat in promoter region)</td>
                <td headers="hd_h_epm1.T.selected_cstb_pathogenic_variants_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">--</td>
                <td headers="hd_h_epm1.T.selected_cstb_pathogenic_variants_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">
                  <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=NT_011515.11">NT_011515.11</ext-link>
                </td>
              </tr>
              <tr>
                <td headers="hd_h_epm1.T.selected_cstb_pathogenic_variants_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.10G&#x0003e;C</td>
                <td headers="hd_h_epm1.T.selected_cstb_pathogenic_variants_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Gly4Arg</td>
                <td headers="hd_h_epm1.T.selected_cstb_pathogenic_variants_1_1_1_3" rowspan="13" valign="middle" align="left" colspan="1">
                  <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=NM_000100.2">NM_000100.2</ext-link>
                  <break/>
                  <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=NP_000091.1">NP_000091.1</ext-link>
                </td>
              </tr>
              <tr>
                <td headers="hd_h_epm1.T.selected_cstb_pathogenic_variants_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.66G&#x0003e;A</td>
                <td headers="hd_h_epm1.T.selected_cstb_pathogenic_variants_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">--</td>
              </tr>
              <tr>
                <td headers="hd_h_epm1.T.selected_cstb_pathogenic_variants_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.67-1G&#x0003e;C</td>
                <td headers="hd_h_epm1.T.selected_cstb_pathogenic_variants_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">--</td>
              </tr>
              <tr>
                <td headers="hd_h_epm1.T.selected_cstb_pathogenic_variants_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.125C&#x0003e;A</td>
                <td headers="hd_h_epm1.T.selected_cstb_pathogenic_variants_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Ser42Ter</td>
              </tr>
              <tr>
                <td headers="hd_h_epm1.T.selected_cstb_pathogenic_variants_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.136C&#x0003e;T</td>
                <td headers="hd_h_epm1.T.selected_cstb_pathogenic_variants_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Gln46Ter</td>
              </tr>
              <tr>
                <td headers="hd_h_epm1.T.selected_cstb_pathogenic_variants_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.149G&#x0003e;A</td>
                <td headers="hd_h_epm1.T.selected_cstb_pathogenic_variants_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Gly50Glu</td>
              </tr>
              <tr>
                <td headers="hd_h_epm1.T.selected_cstb_pathogenic_variants_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.168G&#x0003e;A</td>
                <td headers="hd_h_epm1.T.selected_cstb_pathogenic_variants_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.=&#x000a0;<sup>1,&#x000a0;2</sup></td>
              </tr>
              <tr>
                <td headers="hd_h_epm1.T.selected_cstb_pathogenic_variants_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.168+1_168+18del</td>
                <td headers="hd_h_epm1.T.selected_cstb_pathogenic_variants_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">--</td>
              </tr>
              <tr>
                <td headers="hd_h_epm1.T.selected_cstb_pathogenic_variants_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.168+2_168+21delinsAA</td>
                <td headers="hd_h_epm1.T.selected_cstb_pathogenic_variants_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">--</td>
              </tr>
              <tr>
                <td headers="hd_h_epm1.T.selected_cstb_pathogenic_variants_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.169-2A&#x0003e;G</td>
                <td headers="hd_h_epm1.T.selected_cstb_pathogenic_variants_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">--</td>
              </tr>
              <tr>
                <td headers="hd_h_epm1.T.selected_cstb_pathogenic_variants_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.202C&#x0003e;T</td>
                <td headers="hd_h_epm1.T.selected_cstb_pathogenic_variants_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Arg68Ter</td>
              </tr>
              <tr>
                <td headers="hd_h_epm1.T.selected_cstb_pathogenic_variants_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.212A&#x0003e;C</td>
                <td headers="hd_h_epm1.T.selected_cstb_pathogenic_variants_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Gln71Pro</td>
              </tr>
              <tr>
                <td headers="hd_h_epm1.T.selected_cstb_pathogenic_variants_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.218_219delTC</td>
                <td headers="hd_h_epm1.T.selected_cstb_pathogenic_variants_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Leu73ProfsTer3</td>
              </tr>
            </tbody>
          </table>
          <table-wrap-foot>
            <fn>
              <p>Note on variant classification: Variants listed in the table have been provided by the authors. <italic toggle="yes">GeneReviews</italic> staff have not independently verified the classification of variants.</p>
            </fn>
            <fn>
              <p>Note on nomenclature: <italic toggle="yes">GeneReviews</italic> follows the standard naming conventions of the Human Genome Variation Society (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://varnomen.hgvs.org/">varnomen.hgvs.org</ext-link>). See <related-object link-type="booklink" source-id="gene" document-id="app3" document-type="appendix">Quick Reference</related-object> for an explanation of nomenclature.</p>
            </fn>
            <fn id="epm1.TF.2.1">
              <label>1. </label>
              <p>p.(=) designates that protein has not been analyzed, but no change is expected</p>
            </fn>
            <fn id="epm1.TF.2.2">
              <label>2. </label>
              <p>May produce abnormal splicing [<xref ref-type="bibr" rid="epm1.REF.kagitanishimono.2002.55">Kagitani-Shimono et al 2002</xref>]</p>
            </fn>
          </table-wrap-foot>
        </table-wrap>
        <p><bold>Normal gene product.</bold> Cystatin-B is an inhibitor of several papain-family cysteine proteases, cathepsins, which are lysosomal enzymes. Cystatin-B is a ubiquitously expressed 98-amino acid protein and has a molecular weight of 11 kd. Its physiologic function is unknown. Within cells, cystatin-B shows lysosomal, nuclear, and/or cytosolic localization [<xref ref-type="bibr" rid="epm1.REF.alakurtti.2005.208">Alakurtti et al 2005</xref>]. CSTB has been reported to interact with histones and cathepsin L in the nucleus where it could regulate cathepsin L activity [<xref ref-type="bibr" rid="epm1.REF.ceru.2010.10078">Ceru et al 2010</xref>].</p>
        <p><italic toggle="yes">Cstb</italic>-deficient knockout mice display a phenotype similar to the human disease with progressive ataxia and myoclonic seizures [<xref ref-type="bibr" rid="epm1.REF.pennacchio.1998.251">Pennacchio et al 1998</xref>]. The mice show neuronal apoptosis (especially of cerebellar granule cells), atrophy, and gliosis [<xref ref-type="bibr" rid="epm1.REF.pennacchio.1998.251">Pennacchio et al 1998</xref>, <xref ref-type="bibr" rid="epm1.REF.shannon.2002.1085">Shannon et al 2002</xref>]. Analysis of timing of pathological changes in the brains of <italic toggle="yes">Cstb</italic>-deficient knockout mice have revealed early and localized microglial activation as the first pathological hallmark, followed by activation of astroglia in brain regions where neuron loss subsequently occurs [<xref ref-type="bibr" rid="epm1.REF.tegelberg.2012.40">Tegelberg et al 2012</xref>]. These changes are most pronounced in the thalamocortical system. Microglial activation is accompanied by the presence of inflammatory markers and peripheral immune cells in the brains of <italic toggle="yes">Cstb</italic>-deficient mice, implying the contribution of neuroinflammation to disease pathogenesis [<xref ref-type="bibr" rid="epm1.REF.okuneva.2015.400">Okuneva et al 2015</xref>].</p>
        <p>Impaired redox homeostasis has been reported as a pathophysiologic mechanism in EPM1 whereby dysregulation of cystatin-B-cathepsin B signaling may serve as a critical mechanism coupling oxidative stress to neuronal degeneration and death [<xref ref-type="bibr" rid="epm1.REF.lehtinen.2009.5910">Lehtinen et al 2009</xref>]. Cystatin-B knockout or knockdown sensitizes cerebellar granule neurons to oxidative stress-induced cell death, mediated by cathepsin B. Moreover, the cerebella of <italic toggle="yes">Cstb</italic>-deficient knockout mice show evidence of oxidative damage in vivo, reflected by depletion of antioxidants and increased lipid peroxidation [<xref ref-type="bibr" rid="epm1.REF.lehtinen.2009.5910">Lehtinen et al 2009</xref>].</p>
        <p>There is growing evidence from studies in <italic toggle="yes">Cstb</italic>-deficient knockout mice for the role of altered GABAergic signaling with subsequent loss of GABA inhibition as a mechanism underlying the latent hyperexcitability resulting in myoclonus and seizures [<xref ref-type="bibr" rid="epm1.REF.franceschetti.2007.675">Franceschetti et al 2007</xref>, <xref ref-type="bibr" rid="epm1.REF.buzzi.2012.216">Buzzi et al 2012</xref>, <xref ref-type="bibr" rid="epm1.REF.joensuu.2014.e89321">Joensuu et al 2014</xref>].</p>
        <p><bold>Abnormal gene product.</bold> The major pathogenic variant underlying Unverricht-Lundborg disease, the dodecamer repeat g.513685_513696(30_125), results in a significantly reduced amount of <italic toggle="yes">CSTB</italic> mRNA: 5%-10% of the expression found in controls [<xref ref-type="bibr" rid="epm1.REF.joensuu.2007.185">Joensuu et al 2007</xref>]. Consequently, cells of individuals with Unverricht-Lundborg disease display significantly reduced CSTB protein expression [<xref ref-type="bibr" rid="epm1.REF.alakurtti.2005.208">Alakurtti et al 2005</xref>, <xref ref-type="bibr" rid="epm1.REF.joensuu.2007.185">Joensuu et al 2007</xref>] and reduced CSTB inhibitory activity [<xref ref-type="bibr" rid="epm1.REF.rinne.2002.380">Rinne et al 2002</xref>]. Cathepsin activity is significantly increased [<xref ref-type="bibr" rid="epm1.REF.rinne.2002.380">Rinne et al 2002</xref>].</p>
        <list list-type="bullet">
          <list-item>
            <p>The c.66G&#x0003e;A pathogenic variant affects the last nucleotide of exon 1 and it has experimentally verified to alter splicing.</p>
          </list-item>
          <list-item>
            <p>The c.67-1G&#x0003e;C, c.168+1_168+18del, and c.169-2A&#x0003e;G pathogenic variants affect splice sites and predict splicing defects.</p>
          </list-item>
          <list-item>
            <p>The c.67-1G&#x0003e;C pathogenic variant results in skipping of exon 2 and predicts an in-frame deletion of 34 amino acids.</p>
          </list-item>
          <list-item>
            <p>The c.67-1G&#x0003e;C mutated mRNAs appear to be unstable.</p>
          </list-item>
          <list-item>
            <p>The c.168+1_168+18del pathogenic variant also results in aberrant splicing of <italic toggle="yes">CSTB</italic> with two different transcripts, but the consequence of the c.169-2A&#x0003e;G pathogenic variant as a putative splice site variant has not been experimentally tested.</p>
          </list-item>
          <list-item>
            <p>The c.168+2_168+21delinsAA pathogenic variant is a complex intronic deletion/insertion that involves the donor splice site of intron 2 and is predicted to lead to an aberrant transcript.</p>
          </list-item>
          <list-item>
            <p>The c.168G&#x0003e;A affects the last nucleotide of exon 2 and its consequence as a putative splice site variant has not been experimentally tested.</p>
          </list-item>
          <list-item>
            <p>Pathogenic variants c.125C&#x0003e;A, c.136C&#x0003e;T, c.202C&#x0003e;T, and c.218_219delTC predict truncated proteins of 42, 46, 68, and 74 amino acids, respectively.</p>
          </list-item>
          <list-item>
            <p>The c.202C&#x0003e;T (p.Arg68Ter) mutated transcript and protein are unstable [<xref ref-type="bibr" rid="epm1.REF.alakurtti.2005.208">Alakurtti et al 2005</xref>, <xref ref-type="bibr" rid="epm1.REF.joensuu.2007.185">Joensuu et al 2007</xref>], implying reduced CSTB expression as the primary pathophysiologic mechanism.</p>
          </list-item>
        </list>
        <p>All three of the following missense mutated proteins fail to associate with lysosomes, implying the physiologic importance of CSTB-lysosome association [<xref ref-type="bibr" rid="epm1.REF.alakurtti.2005.208">Alakurtti et al 2005</xref>, <xref ref-type="bibr" rid="epm1.REF.joensuu.2007.185">Joensuu et al 2007</xref>]:</p>
        <list list-type="bullet">
          <list-item>
            <p>The c.10G&#x0003e;C pathogenic variant results in the substitution of a highly conserved glycine to an arginine at amino acid position 4 (p.Gly4Arg), critical for cathepsin binding.</p>
          </list-item>
          <list-item>
            <p>The c.149G&#x0003e;A pathogenic variant results in the substitution of glycine to glutamic acid (p.Gly50Glu) [<xref ref-type="bibr" rid="epm1.REF.joensuu.2007.185">Joensuu et al 2007</xref>]. It affects the highly conserved QVVAG-motif in the first beta-hairpin loop important for the complex formation with cathepsins.</p>
          </list-item>
          <list-item>
            <p>The c.212A&#x0003e;C pathogenic variant results in the substitution of a glutamine at position 71 by a proline (p.Gln71Pro) [<xref ref-type="bibr" rid="epm1.REF.de_haan.2004.1061">de Haan et al 2004</xref>]. The glutamine does not interact directly with target proteases, but is located proximal to the second hairpin loop, which also contributes to protease binding.</p>
          </list-item>
        </list>
      </sec>
      <sec id="epm1.References">
        <title>References</title>
        <sec id="epm1.Literature_Cited">
          <title>Literature Cited</title>
          <ref-list id="epm1.Literature_Cited.reflist0">
            <ref id="epm1.REF.alakurtti.2005.208">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Alakurtti</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Weber</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rinne</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Theil</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>de Haan</surname>
                    <given-names>GJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lindhout</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Salmikangas</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Saukko</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lahtinen</surname>
                    <given-names>U</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lehesjoki</surname>
                    <given-names>AE</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>Loss of lysosomal association of cystatin B proteins representing progressive myoclonus epilepsy, EPM1, mutations.</article-title>
                <source>Eur J Hum Genet</source>
                <volume>13</volume>
                <fpage>208</fpage>
                <lpage>15</lpage>
                <pub-id pub-id-type="pmid">15483648</pub-id>
              </element-citation>
            </ref>
            <ref id="epm1.REF.bassuk.2008.572">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Bassuk</surname>
                    <given-names>AG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wallace</surname>
                    <given-names>RH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Buhr</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Buller</surname>
                    <given-names>AR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Afawi</surname>
                    <given-names>Z</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shimojo</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Miyata</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chen</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gonzalez-Alegre</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Griesbach</surname>
                    <given-names>HL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wu</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nashelsky</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vladar</surname>
                    <given-names>EK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Antic</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ferguson</surname>
                    <given-names>PJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cirak</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Voit</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Scott</surname>
                    <given-names>MP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Axelrod</surname>
                    <given-names>JD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gurnett</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Daoud</surname>
                    <given-names>AS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kivity</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Neufeld</surname>
                    <given-names>MY</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mazarib</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Straussberg</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Walid</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Korczyn</surname>
                    <given-names>AD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Slusarski</surname>
                    <given-names>DC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Berkovic</surname>
                    <given-names>SF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>El-Shanti</surname>
                    <given-names>HI</given-names>
                  </name>
                </person-group>
                <year>2008</year>
                <article-title>A homozygous mutation in human PRICKLE1 causes an autosomal-recessive progressive myoclonus epilepsy-ataxia syndrome.</article-title>
                <source>Am J Hum Genet</source>
                <volume>83</volume>
                <fpage>572</fpage>
                <lpage>81</lpage>
                <pub-id pub-id-type="pmid">18976727</pub-id>
              </element-citation>
            </ref>
            <ref id="epm1.REF.berkovic.2008.673">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Berkovic</surname>
                    <given-names>SF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dibbens</surname>
                    <given-names>LM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Oshlack</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Silver</surname>
                    <given-names>JD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Katerelos</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vears</surname>
                    <given-names>DF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>L&#x000fc;llmann-Rauch</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Blanz</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zhang</surname>
                    <given-names>KW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stankovich</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kalnins</surname>
                    <given-names>RM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dowling</surname>
                    <given-names>JP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Andermann</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Andermann</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Faldini</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>D'Hooge</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vadlamudi</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Macdonell</surname>
                    <given-names>RA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hodgson</surname>
                    <given-names>BL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bayly</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Savige</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mulley</surname>
                    <given-names>JC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Smyth</surname>
                    <given-names>GK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Power</surname>
                    <given-names>DA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Saftig</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bahlo</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <year>2008</year>
                <article-title>Array-based gene discovery with three unrelated subjects shows SCARB2/LIMP-2 deficiency causes myoclonus epilepsy and glomerulosclerosis.</article-title>
                <source>Am J Hum Genet</source>
                <volume>82</volume>
                <fpage>673</fpage>
                <lpage>84</lpage>
                <pub-id pub-id-type="pmid">18308289</pub-id>
              </element-citation>
            </ref>
            <ref id="epm1.REF.boiss_lomax.2013.1146">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Boiss&#x000e9; Lomax</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bayly</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hjalgrim</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>M&#x000f8;ller</surname>
                    <given-names>RS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vlaar</surname>
                    <given-names>AM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Aaberg</surname>
                    <given-names>KM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Marquardt</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gandolfo</surname>
                    <given-names>LC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Willemsen</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kamsteeg</surname>
                    <given-names>EJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>O'Sullivan</surname>
                    <given-names>JD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Korenke</surname>
                    <given-names>GC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bloem</surname>
                    <given-names>BR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>de Coo</surname>
                    <given-names>IF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Verhagen</surname>
                    <given-names>JM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Said</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Prescott</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stray-Pedersen</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rasmussen</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vears</surname>
                    <given-names>DF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lehesjoki</surname>
                    <given-names>AE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Corbett</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bahlo</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gecz</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dibbens</surname>
                    <given-names>LM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Berkovic</surname>
                    <given-names>SF</given-names>
                  </name>
                </person-group>
                <article-title>'North Sea' progressive myoclonus epilepsy: phenotype of subjects with GOSR2 mutation.</article-title>
                <source>Brain.</source>
                <year>2013</year>
                <volume>136</volume>
                <fpage>1146</fpage>
                <lpage>54</lpage>
                <pub-id pub-id-type="pmid">23449775</pub-id>
              </element-citation>
            </ref>
            <ref id="epm1.REF.buzzi.2012.216">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Buzzi</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chikhladze</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Falcicchia</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Paradiso</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lanza</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Soukupova</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Marti</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Morari</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Franceschetti</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Simonato</surname>
                    <given-names>M.</given-names>
                  </name>
                </person-group>
                <article-title>Loss of cortical GABA terminals in Unverricht-Lundborg disease.</article-title>
                <source>Neurobiol Dis.</source>
                <year>2012</year>
                <volume>47</volume>
                <fpage>216</fpage>
                <lpage>24</lpage>
                <pub-id pub-id-type="pmid">22538221</pub-id>
              </element-citation>
            </ref>
            <ref id="epm1.REF.canafoglia.2012.2120">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Canafoglia</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gennaro</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Capovilla</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gobbi</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Boni</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Beccaria</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Viri</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Michelucci</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Agazzi</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Assereto</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Coviello</surname>
                    <given-names>DA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Di Stefano</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rossi Sebastiano</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Franceschetti</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zara</surname>
                    <given-names>F</given-names>
                  </name>
                </person-group>
                <year>2012</year>
                <article-title>Electroclinical presentation and genotype-phenotype relationships in patients with Unverricht-Lundborg disease carrying compound heterozygous CSTB point and indel mutations.</article-title>
                <source>Epilepsia</source>
                <volume>53</volume>
                <fpage>2120</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">23205931</pub-id>
              </element-citation>
            </ref>
            <ref id="epm1.REF.ceru.2010.10078">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Ceru</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Konjar</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Maher</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Repnik</surname>
                    <given-names>U</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Krizaj</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bencina</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Renko</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nepveu</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zerovnik</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Turk</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kopitar-Jerala</surname>
                    <given-names>N.</given-names>
                  </name>
                </person-group>
                <article-title>Stefin B interacts with histones and cathepsin L in the nucleus.</article-title>
                <source>J Biol Chem.</source>
                <year>2010</year>
                <volume>285</volume>
                <fpage>10078</fpage>
                <lpage>86</lpage>
                <pub-id pub-id-type="pmid">20075068</pub-id>
              </element-citation>
            </ref>
            <ref id="epm1.REF.corbett.2011.657">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Corbett</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schwake</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bahlo</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dibbens</surname>
                    <given-names>LM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lin</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gandolfo</surname>
                    <given-names>LC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vears</surname>
                    <given-names>DF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>O'Sullivan</surname>
                    <given-names>JD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Robertson</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bayly</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gardner</surname>
                    <given-names>AE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vlaar</surname>
                    <given-names>AM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Korenke</surname>
                    <given-names>GC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bloem</surname>
                    <given-names>BR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>de Coo</surname>
                    <given-names>IF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Verhagen</surname>
                    <given-names>JM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lehesjoki</surname>
                    <given-names>AE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gecz</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Berkovic</surname>
                    <given-names>SF</given-names>
                  </name>
                </person-group>
                <year>2011</year>
                <article-title>A mutation in the Golgi Qb-SNARE gene GOSR2 causes progressive myoclonus epilepsy with early ataxia.</article-title>
                <source>Am J Hum Genet</source>
                <volume>88</volume>
                <fpage>657</fpage>
                <lpage>63</lpage>
                <pub-id pub-id-type="pmid">21549339</pub-id>
              </element-citation>
            </ref>
            <ref id="epm1.REF.danner.2009.81">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Danner</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Julkunen</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Khyuppenen</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hukkanen</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>K&#x000f6;n&#x000f6;nen</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>S&#x000e4;is&#x000e4;nen</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Koskenkorva</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vanninen</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lehesjoki</surname>
                    <given-names>AE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>K&#x000e4;lvi&#x000e4;inen</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mervaala</surname>
                    <given-names>E</given-names>
                  </name>
                </person-group>
                <year>2009</year>
                <article-title>Altered cortical inhibition in Unverricht-Lundborg type progressive myoclonus epilepsy (EPM1).</article-title>
                <source>Epilepsy Res</source>
                <volume>85</volume>
                <fpage>81</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">19321308</pub-id>
              </element-citation>
            </ref>
            <ref id="epm1.REF.de_haan.2004.1061">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>de Haan</surname>
                    <given-names>GJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Halley</surname>
                    <given-names>DJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Doelman</surname>
                    <given-names>JC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Geesink</surname>
                    <given-names>HH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Augustijn</surname>
                    <given-names>PB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jager-Jongkind</surname>
                    <given-names>AD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Majoie</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bader</surname>
                    <given-names>AJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Leliefeld-Ten Doeschate</surname>
                    <given-names>LA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Deelen</surname>
                    <given-names>WH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bertram</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lehesjoki</surname>
                    <given-names>AE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lindhout</surname>
                    <given-names>D</given-names>
                  </name>
                </person-group>
                <year>2004</year>
                <article-title>Univerricht-Lundborg disease: underdiagnosed in the Netherlands.</article-title>
                <source>Epilepsia</source>
                <volume>45</volume>
                <fpage>1061</fpage>
                <lpage>3</lpage>
                <pub-id pub-id-type="pmid">15329070</pub-id>
              </element-citation>
            </ref>
            <ref id="epm1.REF.edwards.2002.1447">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Edwards</surname>
                    <given-names>MJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hargreaves</surname>
                    <given-names>IP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Heales</surname>
                    <given-names>SJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jones</surname>
                    <given-names>SJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ramachandran</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bhatia</surname>
                    <given-names>KP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sisodiya</surname>
                    <given-names>S</given-names>
                  </name>
                </person-group>
                <year>2002</year>
                <article-title>N-acetylcysteine and Unverricht-Lundborg disease: variable response and possible side effects.</article-title>
                <source>Neurology</source>
                <volume>59</volume>
                <fpage>1447</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">12427904</pub-id>
              </element-citation>
            </ref>
            <ref id="epm1.REF.eldridge.1983.838">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Eldridge</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Iivanainen</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stern</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Koerber</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wilder</surname>
                    <given-names>BJ</given-names>
                  </name>
                </person-group>
                <year>1983</year>
                <article-title>"Baltic" myoclonus epilepsy: hereditary disorder of childhood made worse by phenytoin.</article-title>
                <source>Lancet</source>
                <volume>2</volume>
                <fpage>838</fpage>
                <lpage>42</lpage>
                <pub-id pub-id-type="pmid">6137660</pub-id>
              </element-citation>
            </ref>
            <ref id="epm1.REF.erdinc.2010.1">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Erdinc</surname>
                    <given-names>OO</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Joensuu</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ilgen-Uslu</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bebek</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>&#x000d6;zkara</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tutkavul</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>G&#x000fc;nd&#x000fc;z</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lehesjoki</surname>
                    <given-names>AE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Baykan</surname>
                    <given-names>B</given-names>
                  </name>
                </person-group>
                <year>2010</year>
                <article-title>Unverricht-Lundborg Disease in Turkey: Delineating the phenotype between cystatin B mutation positive and negative cases.</article-title>
                <source>J Neurol Sci (Turk)</source>
                <volume>27</volume>
                <fpage>1</fpage>
                <lpage>11</lpage>
              </element-citation>
            </ref>
            <ref id="epm1.REF.franceschetti.2007.675">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Franceschetti</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sancini</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Buzzi</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zucchini</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Paradiso</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Magnaghi</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Frassoni</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chikhladze</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Avanzini</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Simonato</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <year>2007</year>
                <article-title>A pathogenetic hypothesis of Unverricht-Lundborg disease onset and progression.</article-title>
                <source>Neurobiol Dis</source>
                <volume>25</volume>
                <fpage>675</fpage>
                <lpage>85</lpage>
                <pub-id pub-id-type="pmid">17188503</pub-id>
              </element-citation>
            </ref>
            <ref id="epm1.REF.joensuu.2007.185">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Joensuu</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kuronen</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Alakurtti</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tegelberg</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hakala</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Aalto</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Huopaniemi</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Aula</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Michellucci</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Eriksson</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lehesjoki</surname>
                    <given-names>AE</given-names>
                  </name>
                </person-group>
                <year>2007</year>
                <article-title>Cystatin B: mutation detection, alternative splicing and expression in progressive myclonus epilepsy of Unverricht-Lundborg type (EPM1) patients.</article-title>
                <source>Eur J Hum Genet</source>
                <volume>15</volume>
                <fpage>185</fpage>
                <lpage>93</lpage>
                <pub-id pub-id-type="pmid">17003839</pub-id>
              </element-citation>
            </ref>
            <ref id="epm1.REF.joensuu.2014.e89321">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Joensuu</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tegelberg</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Reinmaa</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Segerstr&#x000e5;le</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hakala</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pehkonen</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Korpi</surname>
                    <given-names>ER</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tyynel&#x000e4;</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Taira</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hovatta</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kopra</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lehesjoki</surname>
                    <given-names>AE</given-names>
                  </name>
                </person-group>
                <article-title>Gene expression alterations in the cerebellum and granule neurons of Cstb(-/-) mouse are associated with early synaptic changes and inflammation.</article-title>
                <source>PLoS One.</source>
                <year>2014</year>
                <volume>9</volume>
                <fpage>e89321</fpage>
                <pub-id pub-id-type="pmid">24586687</pub-id>
              </element-citation>
            </ref>
            <ref id="epm1.REF.kagitanishimono.2002.55">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Kagitani-Shimono</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Imai</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Okamoto</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ono</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Okada</surname>
                    <given-names>S</given-names>
                  </name>
                </person-group>
                <year>2002</year>
                <article-title>Unverricht-Lundborg disease with cystatin B gene abnormalities.</article-title>
                <source>Pediatr Neurol</source>
                <volume>26</volume>
                <fpage>55</fpage>
                <lpage>60</lpage>
                <pub-id pub-id-type="pmid">11814737</pub-id>
              </element-citation>
            </ref>
            <ref id="epm1.REF.k_lvi_inen.2008.549">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>K&#x000e4;lvi&#x000e4;inen</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Khyuppenen</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Koskenkorva</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Eriksson</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vanninen</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mervaala</surname>
                    <given-names>E</given-names>
                  </name>
                </person-group>
                <year>2008</year>
                <article-title>Clinical picture of EPM1-Unverricht-Lundborg disease.</article-title>
                <source>Epilepsia</source>
                <volume>49</volume>
                <fpage>549</fpage>
                <lpage>56</lpage>
                <pub-id pub-id-type="pmid">18325013</pub-id>
              </element-citation>
            </ref>
            <ref id="epm1.REF.koskenkorva.2011.515">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Koskenkorva</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hypp&#x000f6;nen</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Aiki&#x000e4;</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mervaala</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kiviranta</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Eriksson</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lehesjoki</surname>
                    <given-names>AE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vanninen</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>K&#x000e4;lvi&#x000e4;inen</surname>
                    <given-names>R</given-names>
                  </name>
                </person-group>
                <article-title>Severer phenotype in Unverricht-Lundborg disease (EPM1) patients compound heterozygous for the dodecamer repeat expansion and the c.202C&#x0003e;T mutation in the CSTB gene.</article-title>
                <source>Neurodegener Dis.</source>
                <year>2011</year>
                <volume>8</volume>
                <fpage>515</fpage>
                <lpage>22</lpage>
                <pub-id pub-id-type="pmid">21757863</pub-id>
              </element-citation>
            </ref>
            <ref id="epm1.REF.koskiniemi.1998.344">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Koskiniemi</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Van Vleymen</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hakamies</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lamusuo</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Taalas</surname>
                    <given-names>J</given-names>
                  </name>
                </person-group>
                <year>1998</year>
                <article-title>Piracetam relieves symptoms in progressive myoclonus epilepsy: a multicentre, randomised, double blind, crossover study comparing the efficacy and safety of three dosages of oral piracetam with placebo.</article-title>
                <source>J Neurol Neurosurg Psychiatry</source>
                <volume>64</volume>
                <fpage>344</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">9527146</pub-id>
              </element-citation>
            </ref>
            <ref id="epm1.REF.lehtinen.2009.5910">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Lehtinen</surname>
                    <given-names>MK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tegelberg</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schipper</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Su</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zukor</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Manninen</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kopra</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Joensuu</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hakala</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bonni</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lehesjoki</surname>
                    <given-names>A-E</given-names>
                  </name>
                </person-group>
                <year>2009</year>
                <article-title>Cystatin B deficiency sensitizes neurons to oxidative stress in progressive myoclonus epilepsy, EPM1.</article-title>
                <source>J Neurosci</source>
                <volume>29</volume>
                <fpage>5910</fpage>
                <lpage>5</lpage>
                <pub-id pub-id-type="pmid">19420257</pub-id>
              </element-citation>
            </ref>
            <ref id="epm1.REF.magaudda.2006.860">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Magaudda</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ferlazzo</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nguyen</surname>
                    <given-names>VH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Genton</surname>
                    <given-names>P</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>Unverricht-Lundborg disease, a condition with self-limited progression: long-term follow-up of 20 patients.</article-title>
                <source>Epilepsia</source>
                <volume>47</volume>
                <fpage>860</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">16686650</pub-id>
              </element-citation>
            </ref>
            <ref id="epm1.REF.medina.2005.307">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Medina</surname>
                    <given-names>MT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Martinez-Juarez</surname>
                    <given-names>IE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Duron</surname>
                    <given-names>RM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Genton</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Guerrini</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dravet</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bureau</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Perez-Gosiengfiao</surname>
                    <given-names>KT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Amador</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bailey</surname>
                    <given-names>JN</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chaves-Sell</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Delgado-Escueta</surname>
                    <given-names>AV</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>Treatment of myoclonic epilepsies of childhood, adolescence, and adulthood.</article-title>
                <source>Adv Neurol</source>
                <volume>95</volume>
                <fpage>307</fpage>
                <lpage>23</lpage>
                <pub-id pub-id-type="pmid">15508934</pub-id>
              </element-citation>
            </ref>
            <ref id="epm1.REF.muona.2015.39">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Muona</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Berkovic</surname>
                    <given-names>SF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dibbens</surname>
                    <given-names>LM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Oliver</surname>
                    <given-names>KL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Maljevic</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bayly</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Joensuu</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Canafoglia</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Franceschetti</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Michelucci</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Markkinen</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Heron</surname>
                    <given-names>SE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hildebrand</surname>
                    <given-names>MS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Andermann</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Andermann</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gambardella</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tinuper</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Licchetta</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Scheffer</surname>
                    <given-names>IE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Criscuolo</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Filla</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ferlazzo</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ahmad</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ahmad</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Baykan</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Said</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Topcu</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Riguzzi</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>King</surname>
                    <given-names>MD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ozkara</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Andrade</surname>
                    <given-names>DM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Engelsen</surname>
                    <given-names>BA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Crespel</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lindenau</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lohmann</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Saletti</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Massano</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Privitera</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Espay</surname>
                    <given-names>AJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kauffmann</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Duchowny</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>M&#x000f8;ller</surname>
                    <given-names>RS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Straussberg</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Afawi</surname>
                    <given-names>Z</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ben-Zeev</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Samocha</surname>
                    <given-names>KE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Daly</surname>
                    <given-names>MJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Petrou</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lerche</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Palotie</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lehesjoki</surname>
                    <given-names>AE</given-names>
                  </name>
                </person-group>
                <article-title>A recurrent de novo mutation in KCNC1 causes progressive myoclonus epilepsy.</article-title>
                <source>Nat Genet.</source>
                <year>2015</year>
                <volume>47</volume>
                <fpage>39</fpage>
                <lpage>46</lpage>
                <pub-id pub-id-type="pmid">25401298</pub-id>
              </element-citation>
            </ref>
            <ref id="epm1.REF.okuneva.2015.400">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Okuneva</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>K&#x000f6;rber</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Li</surname>
                    <given-names>Z</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tian</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Joensuu</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kopra</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lehesjoki</surname>
                    <given-names>AE</given-names>
                  </name>
                </person-group>
                <article-title>Abnormal microglial activation in the Cstb(-/-) mouse, a model for progressive myoclonus epilepsy, EPM1.</article-title>
                <source>Glia.</source>
                <year>2015</year>
                <volume>63</volume>
                <fpage>400</fpage>
                <lpage>11</lpage>
                <pub-id pub-id-type="pmid">25327891</pub-id>
              </element-citation>
            </ref>
            <ref id="epm1.REF.pennacchio.1998.251">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Pennacchio</surname>
                    <given-names>LA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bouley</surname>
                    <given-names>DM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Higgins</surname>
                    <given-names>KM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Scott</surname>
                    <given-names>MP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Noebels</surname>
                    <given-names>JL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Myers</surname>
                    <given-names>RM</given-names>
                  </name>
                </person-group>
                <year>1998</year>
                <article-title>Progressive ataxia, myoclonic epilepsy and cerebellar apoptosis in cystatin B-deficient mice.</article-title>
                <source>Nat Genet</source>
                <volume>20</volume>
                <fpage>251</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">9806543</pub-id>
              </element-citation>
            </ref>
            <ref id="epm1.REF.pinto.2012.187">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Pinto</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Freitas</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Duarte</surname>
                    <given-names>AJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ribeiro</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ribeiro</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lima</surname>
                    <given-names>JL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chaves</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Amaral</surname>
                    <given-names>O</given-names>
                  </name>
                </person-group>
                <year>2012</year>
                <article-title>Unverricht-Lundborg disease: homozygosity for a new splicing mutation in the cystatin B gene.</article-title>
                <source>Epilepsy Res</source>
                <volume>99</volume>
                <fpage>187</fpage>
                <lpage>90</lpage>
                <pub-id pub-id-type="pmid">22154554</pub-id>
              </element-citation>
            </ref>
            <ref id="epm1.REF.rinne.2002.380">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Rinne</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Saukko</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jarvinen</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lehesjoki</surname>
                    <given-names>AE</given-names>
                  </name>
                </person-group>
                <year>2002</year>
                <article-title>Reduced cystatin B activity correlates with enhanced cathepsin activity in progressive myoclonus epilepsy.</article-title>
                <source>Ann Med</source>
                <volume>34</volume>
                <fpage>380</fpage>
                <lpage>5</lpage>
                <pub-id pub-id-type="pmid">12452481</pub-id>
              </element-citation>
            </ref>
            <ref id="epm1.REF.shahwan.2005.239">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Shahwan</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Farrell</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Delanty</surname>
                    <given-names>N</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>Progressive myoclonic epilepsies: a review of genetic and therapeutic aspects.</article-title>
                <source>Lancet Neurol</source>
                <volume>4</volume>
                <fpage>239</fpage>
                <lpage>48</lpage>
                <pub-id pub-id-type="pmid">15778103</pub-id>
              </element-citation>
            </ref>
            <ref id="epm1.REF.shannon.2002.1085">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Shannon</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pennacchio</surname>
                    <given-names>LA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Houseweart</surname>
                    <given-names>MK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Minassian</surname>
                    <given-names>BA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Myers</surname>
                    <given-names>RM</given-names>
                  </name>
                </person-group>
                <year>2002</year>
                <article-title>Neuropathological changes in a mouse model of progressive myoclonus epilepsy: cystatin B deficiency and Unverricht-Lundborg disease.</article-title>
                <source>J Neuropathol Exp Neurol</source>
                <volume>61</volume>
                <fpage>1085</fpage>
                <lpage>91</lpage>
                <pub-id pub-id-type="pmid">12484571</pub-id>
              </element-citation>
            </ref>
            <ref id="epm1.REF.smith.2000.1046">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Smith</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shatz</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Elisevich</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bespalova</surname>
                    <given-names>IN</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Burmeister</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <year>2000</year>
                <article-title>Effects of vagus nerve stimulation on progressive myoclonus epilepsy of Unverricht-Lundborg type.</article-title>
                <source>Epilepsia</source>
                <volume>41</volume>
                <fpage>1046</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">10961635</pub-id>
              </element-citation>
            </ref>
            <ref id="epm1.REF.tegelberg.2012.40">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Tegelberg</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kopra</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Joensuu</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cooper</surname>
                    <given-names>JD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lehesjoki</surname>
                    <given-names>AE</given-names>
                  </name>
                </person-group>
                <year>2012</year>
                <article-title>Early microglial activation precedes neuronal loss in the brain of the Cstb-/- mouse model of progressive myoclonus epilepsy, EPM1.</article-title>
                <source>J Neuropathol Exp Neurol</source>
                <volume>71</volume>
                <fpage>40</fpage>
                <lpage>53</lpage>
                <pub-id pub-id-type="pmid">22157618</pub-id>
              </element-citation>
            </ref>
          </ref-list>
        </sec>
        <sec id="epm1.Suggested_Reading">
          <title>Suggested Reading</title>
          <ref-list id="epm1.Suggested_Reading.reflist0">
            <ref id="epm1.REF.joensuu.2008.557">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Joensuu</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lehesjoki</surname>
                    <given-names>AE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kopra</surname>
                    <given-names>O</given-names>
                  </name>
                </person-group>
                <year>2008</year>
                <article-title>Molecular background of EPM1-Unverricht-Lundborg disease.</article-title>
                <source>Epilepsia</source>
                <volume>49</volume>
                <fpage>557</fpage>
                <lpage>63</lpage>
                <pub-id pub-id-type="pmid">18028412</pub-id>
              </element-citation>
            </ref>
            <ref id="epm1.REF.noebels">
              <mixed-citation publication-type="book">Noebels JL. The inherited epilepsies. In: Valle D, Beaudet AL, Vogelstein B, Kinzler KW, Antonarakis SE, Ballabio A, Gibson K, Mitchell G, eds. <italic toggle="yes">The Online Metabolic and Molecular Bases of Inherited Disease (OMMBID)</italic>. Chapter 230. New York, NY: McGraw-Hill. Available <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://ommbid.mhmedical.com/">online</ext-link>.</mixed-citation>
            </ref>
          </ref-list>
        </sec>
      </sec>
      <sec id="epm1.Chapter_Notes">
        <title>Chapter Notes</title>
        <sec id="epm1.Author_History">
          <title>Author History</title>
          <p>Reetta K&#x000e4;lvi&#x000e4;inen, MD, PhD (2007-present) Marja-Leena Koskiniemi, MD, PhD; University of Helsinki (2004-2007) Anna-Elina Lehesjoki, MD, PhD (2004-present)</p>
        </sec>
        <sec id="epm1.Revision_History">
          <title>Revision History</title>
          <list list-type="bullet">
            <list-item>
              <p>26 November 2014 (me) Comprehensive update posted live</p>
            </list-item>
            <list-item>
              <p>18 June 2009 (me) Comprehensive update posted live</p>
            </list-item>
            <list-item>
              <p>18 September 2007 (cd) Revision: sequence analysis available on a clinical basis</p>
            </list-item>
            <list-item>
              <p>12 February 2007 (me) Comprehensive update posted to live Web site</p>
            </list-item>
            <list-item>
              <p>24 June 2004 (me) Review posted to live Web site</p>
            </list-item>
            <list-item>
              <p>6 February 2004 (ael) Original submission</p>
            </list-item>
          </list>
        </sec>
      </sec>
    </body>
  </book-part>
</book-part-wrapper>
